Pirimidine derivatives as hepatoprotective agents
The International Journal of Risk & Safety in Medicine
|December 8, 2015
Summary
The novel pyrimidine derivative, L-ascorbate 1-(2-hydroxyethyl)-4,6-dimethyl-1,2-dihydro-pirimidine-2-one (Asc-Xym), demonstrates significant hepatoprotective properties. Asc-Xym exhibits superior efficacy in protecting the liver against toxic damage compared to Xymedon and Thiotriazolin.
Area of Science:
- Pharmacology
- Hepatology
- Medicinal Chemistry
Background:
- Hepatoprotective medicine development is a key research area in Russia and globally.
- Pyrimidine derivatives, like Xymedon, have shown promise in treating liver disorders.
- This study focuses on evaluating new pyrimidine derivatives for enhanced hepatoprotective effects.
Purpose of the Study:
- To evaluate the hepatoprotective potential of a new Xymedon derivative, Asc-Xym, against carbon tetrachloride-induced liver damage in rats.
- To compare the efficacy of Asc-Xym with existing compounds like Xymedon and Thiotriazolin.
Main Methods:
- Carbon tetrachloride (CTC) was used to induce toxic liver damage in rats.
- Two experimental schemes were employed: preventive (pre-treatment with compounds) and therapeutic (post-treatment).
- Biochemical markers (AlAT, AsAT, total protein, de Rytis coefficient) and histological analysis were used to assess liver damage and protection.
Main Results:
- CTC induced significant alterations in liver enzymes and histological damage in control groups.
- Asc-Xym treatment, particularly in the therapeutic scheme, showed biochemical and histological improvements closest to reference values.
- Asc-Xym demonstrated a higher degree of hepatoprotection compared to Xymedon and Thiotriazolin.
Conclusions:
- The novel compound Asc-Xym possesses significant hepatoprotective properties.
- Asc-Xym exhibits superior efficacy in mitigating carbon tetrachloride-induced liver damage compared to Xymedon and Thiotriazolin.
- Asc-Xym represents a promising candidate for further development as a hepatoprotective agent.
More Related Videos
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
61
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
61
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
344
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
344
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
296
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
296
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
256
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
335
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
335
01:15Anthelminthic Agents
45
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
45